HS-IT101

Phase 1Biologic

TThe Affiliated Hospital of Qingdao University

HS-IT101 is one of 57 biologic programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Breast CancerPhase 1

Active, not recruiting

MelanomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Lexiscan

Astellas

Preclinical

1 3

Adenocard

Astellas

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Aquasol E

NNational Eye Institute (NEI)

Motexafin Gadolinium

1 9

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 10

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Breast Cancer

NCT05505812

Phase 1Not yet recruiting

Advanced Solid Tumor

NCT05539768

Q1 2028

Phase 1Recruiting

Advanced Solid Tumors

NCT06342336

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer

Not yet recruiting·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT05505812·10 enrolled

Advanced Solid Tumor1 trial

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor

Not yet recruiting·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT05539768·8 enrolled

Melanoma1 trial

HS-IT101 Injection in the Treatment of Advanced Melanoma

Enrolling by invitation·QQingdao Sino-Cell Biomedicine Co., Ltd.·Phase 1·NCT06941818·10 enrolled

Advanced Solid Tumors1 trial

HS-IT101 Injection in the Treatment of Advanced Solid Tumors

Recruiting·QQingdao Sino-Cell Biomedicine Co., Ltd.·Phase 1·NCT06342336·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for HS-IT101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HS-IT101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HS-IT101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Hospital of Qingdao University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TThe Affiliated Hospital of Qingdao University

HS-IT101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Trials by Indication[1]

Breast Cancer1 trial

Advanced Solid Tumor1 trial

Melanoma1 trial

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News